The federal Judicial Panel on Multidistrict Litigation listed 12,743 hair relaxer actions pending on November 2. Reuters, citing the women's attorneys, reports that four women's cancer cases, the first to go to trial, settled with L'Oreal USA and other makers for a confidential sum. L'Oreal has said a 2022 study did not establish a causal link, Reuters reports.

With 12,743 federal relaxer suits pending on November 2, four women's cancer cases settled with L'Oreal USA and other makers during a Cook County, Illinois, trial, Reuters reports, citing the women's attorneys. The women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, alleged that years of using chemical hair straighteners caused their gynecologic cancers, according to Reuters; their cases, the first to go to trial, settled for a confidential sum, the lawyers said. The settlement came on Monday, November 16, a week after the trial began with jury selection on November 9, according to Reuters. The federal actions remain before a different court.
Reuters reports that the products, marketed under names including Dark and Lovely and Optimum, promise to permanently straighten textured hair and have been widely marketed to Black women. The first lawsuits followed a 2022 National Institutes of Health study that found women who used the products several times a year were more than twice as likely to develop uterine cancer, the report says. L'Oreal has said the study did not establish a causal link between the use of the products and any conditions alleged by the plaintiffs, according to Reuters. In the same report, a spokesperson for L'Oreal said the company’s highest priority is the health and wellbeing of its consumers and that it remains confident in the safety of its SoftSheen-Carson brand hair products, which include hair relaxers. “L’Oréal USA strictly follows all regulations in every market in which it operates, and its products are always subject to a rigorous scientific evaluation of their safety,” the spokesperson said. The reported settlement ended this trial without a jury finding about whether the products caused the women's cancers.
The 4 sources behind this story: 2 court records and 2 other sources, each linked with what it shows. Free with the weekly Litigation Sentinel brief.
The four women are among thousands who have sued the companies, Reuters reports. In a statement Reuters quotes, an attorney for the women said she hoped the settlement would give them “a sense of justice.” They sued L'Oreal's U.S. subsidiary and several other makers of the products in Cook County in 2023 and 2024. Their cases proceeded in state court, separate from the federal actions gathered before U.S. District Judge Mary M. Rowland in the Northern District of Illinois.
The women's allegations raised the question whether the straighteners caused their cancers. Reuters reports that the trial began with jury selection. The settlement resolved their cases during trial and left that question without a jury answer in this proceeding.
Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.
The Judicial Panel on Multidistrict Litigation's November 2 report lists 12,743 actions then pending in the federal hair relaxer MDL, short for multidistrict litigation: thousands of similar federal cases gathered before one judge. It sits fourth on the report's list, which orders active MDLs by actions pending. Over the life of the MDL, the report counts 17,018 actions in total, a figure that includes cases no longer pending. Reuters, citing court records, puts the federal group at more than 12,700 cases centralized before a judge in federal court in Chicago.
Judge Rowland oversees that proceeding. The court's MDL 3060 page describes filing in another federal court before transfer or filing directly in the Northern District of Illinois. It says new cases must be filed separately and directs those filing in the Northern District to Case Management Order Nos. 2 and 3. The Cook County trial was a state court trial outside that process. It was not a federal bellwether, meaning a test trial for thousands of similar suits.
**Analysis:** The first trial produced no verdict; Reuters reports that the cases settled for a confidential sum. The first lawsuits followed the 2022 study, and L'Oreal has said the study did not establish a causal link, according to the same report. The scale sits in the panel's count of 12,743 pending federal actions.
The dispute has also reached state governments. Reuters reports that Arizona and Minnesota sued L'Oreal over the products this year, alleging that the company had misled women about their safety. Those are the states' allegations, not findings in the four settled cases.
The scoreboard after the first trial: four women's cases settled for a confidential sum, according to Reuters, and 12,743 federal actions were pending before Judge Rowland in the panel's November 2 count.
The readiness check has five questions about your reported litigation practices. Use the summary to choose an operating question to explore.
Take the 2-minute readiness check →Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.